Detalles de la búsqueda
1.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Clin Infect Dis;
76(4): 720-729, 2023 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35235656
2.
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.
Thorax;
70(4): 359-67, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25661113
3.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study.
Open Forum Infect Dis;
11(5): ofae227, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38737429
4.
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.
Viruses;
16(3)2024 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38543770
5.
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study.
Open Forum Infect Dis;
11(1): ofad626, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38213637
6.
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
J Acquir Immune Defic Syndr;
2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38346427
7.
A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC).
BMC Public Health;
11: 528, 2011 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-21726445
8.
Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Pharmacoeconomics;
27(3): 231-45, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19354343
9.
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Pharmacotherapy;
39(1): 40-54, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30414209
10.
Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials.
Open Forum Infect Dis;
5(5): ofy086, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29766019
11.
Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Pharmacoeconomics;
33(2): 137-48, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25213036
12.
Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen.
Per Med;
10(6): 601-611, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29776195
13.
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
Pharmacoeconomics;
31(5): 403-13, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23576017
14.
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.
PLoS One;
7(8): e44064, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22952875
15.
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Pharmacoeconomics;
29(12): 1051-62, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21967156
Resultados
1 -
15
de 15
1
Próxima >
>>